DoH, Pfizer host high-level workshop to advance real world data in healthcare research
ABU DHABI (WAM)The Department of Health – Abu Dhabi (DoH), in collaboration with Pfizer Gulf, hosted a specialised workshop titled 'Harnessing the Power of Real World Data in Healthcare Research', as part of the strategic Memorandum of Understanding (MoU) signed between the two entities in 2024.The MoU underscores a shared commitment to strengthening Abu Dhabi's position, as a global hub for healthcare innovation, by advancing real-world data capabilities and enabling data-driven, evidence-based decision-making.The workshop brought together more than 60 researchers, data scientists, pharmacists, and healthcare professionals from across Abu Dhabi's leading hospitals and academic institutions to explore how real-world evidence can be leveraged to advance research, improve health outcomes, and enable more personalised care.The event served as a platform to foster knowledge exchange and scientific dialogue, and to support Abu Dhabi's ambition to become a global centre for health and life sciences. Through the MoU, Pfizer and DoH are working jointly to enhance real-world data capabilities, with a focus on driving local evidence generation and building research capacity that addresses both national and global healthcare priorities.Dr. Nadine Tarcha, Medical Director at Pfizer Gulf, highlighted the company's role in shaping the future of healthcare research through meaningful partnerships, 'At Pfizer, we believe real-world data is key to generating insights that complement clinical trials and accelerate patient-centred innovation. Through this collaboration with the Department of Health, we aim to empower local research, strengthen evidence generation, and improve access to better health outcomes.'The workshop agenda included a range of expert-led discussions on the use of real-world data from national databases, differences between real-world evidence and traditional clinical trials, study design and bias, regulatory considerations, and governance models for data access.A panel discussion was also held featuring representatives from the Department of Health, the UAE Genome Programme, M42, and global Pfizer real-world evidence leaders to explore the potential of Abu Dhabi's Trusted Research Environment in advancing scientific discovery.
This initiative is part of a broader effort under the MoU to foster long-term public-private partnerships that enhance Abu Dhabi's global competitiveness in biomedical research, genomics, and precision medicine. It reinforces both entities' commitment to advancing data-driven solutions that improve health outcomes in the UAE and beyond.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Al Etihad
10 hours ago
- Al Etihad
Abu Dhabi: Malaffi reaches 3.5 billion clinical records
14 Aug 2025 11:36 ABU DHABI (ALETIHAD) Malaffi, the region's first Health Information Exchange (HIE) platform and a strategic initiative of the Department of Health – Abu Dhabi (DoH), operated by M42's Abu Dhabi Health Data Services (ADHDS), has achieved a significant milestone by reaching 3.5 billion clinical records, representing 12.7 million unique patient profiles across Abu Dhabi to help progress the UAE's advance in precision and preventive care. The milestone highlights Malaffi's ongoing evolution as a cutting-edge Health Information Exchange platform that supports innovation and excellence in the delivery of healthcare services. Malaffi continues to improve healthcare professionals' access to and utilisation of critical patient information. With connections to nearly all healthcare facilities – including hospitals, clinics and pharmacies - in the Emirate, Malaffi now supports 53,476 authorised users, from doctors and nurses to allied health professionals across 3,072 healthcare facilities in Abu platform's latest enhancements expand its capabilities with the addition of over 160,000 M42 Pharmacogenomics Reports, offering personalised insights into patients' genetic responses to medications to optimise treatment plans. Furthermore, new diagnostic test results across key specialities—such as Mental Health, Ophthalmology, Otolaryngology, and Respiratory Diagnostics—provide clinicians with deeper insights to elevate patient advancements are complemented by features like the Radiology Image Exchange, allowing access to radiology images from over 60 facilities to all authorised clinical users, and the AI-powered Patient Risk Profile, which predicts risks for chronic conditions and acute events. Together, these innovations streamline workflows, enhance decision-making and support better healthcare Noura Khamis Al Ghaithi, Undersecretary of the Department of Health – Abu Dhabi (DoH), said: 'Malaffi's access to 3.5 billion medical records marks a pivotal milestone, reflecting the Department of Health – Abu Dhabi's steadfast commitment to creating the world's most intelligent, patient-centric healthcare system." She added: "By harnessing innovative healthcare solutions powered by artificial intelligence, such as pharmacogenomics and predictive analytics, Malaffi continues to advance, enabling healthcare providers to deliver services that meet the highest standards of care and empower community members to lead healthier lives. This achievement further strengthens Abu Dhabi's position as a globally leading digital healthcare ecosystem.'Kareem Shaheen, CEO of M42's Digital Health Solutions platform, added: "This milestone is a testament to the collaborative efforts of Abu Dhabi's healthcare ecosystem and the visionary leadership of the Department of Health." He added: "Aligned with M42's mission to advance innovation in health for people, Malaffi is securely connecting critical patient information with clinicians to enable informed decision-making, elevate healthcare standards and deliver quality patient outcomes. With every new feature and service we introduce, we are revolutionising the way care is delivered, ensuring better outcomes for patients and providers alike." With 3.5 billion clinical records now connected, Malaffi plays a key role in enhancing Abu Dhabi's healthcare ecosystem and providing a strong foundation for research, from AI-driven analytics to advanced treatments. As Abu Dhabi progresses in its digital transformation, Malaffi supports the Emirate's growth by offering innovative solutions that benefit patients and providers, reinforcing its position as a global hub for healthcare innovation. Source: Aletihad - Abu Dhabi
Zawya
a day ago
- Zawya
Oman to produce medical diagnostic machines locally
A strategic Memorandum of Understanding (MoU) was signed by Dr Mohammad Mahmoodi, CEO of Carbon Technologies, and Dr Frank Vitzthum, Board Member and CTO of R-Biopharm, Germany, in the presence of Dr Rahma bint Ibrahim al Mahrouqiyah, Minister of Higher Education, Research and Innovation, on Tuesday. Under the MoU, advanced diagnostic manufacturing will be localised in Oman, supporting technology transfer and enhancing the country's health innovation ecosystem. The partnership will enable integration of state-of-the-art assay technologies into its local production lines, supporting both national and regional healthcare priorities. 'It is a milestone MoU in Oman's journey towards eliminating tuberculosis and other diseases from the country, and both communicable diseases and NCDs,' said Dr Rahma bint Ibrahim al Mahrouqiyah, Minister of Higher Education, Research and Innovation. 'I'm optimistic and this will pave the way for various scientific advancements in the country, especially when it is located near SQU and within the Innovation Park Muscat. We have begun, and we look forward to having an international consortium to eradicate both communicable and non-communicable diseases. We look forward to collaborating with regional, national and international partners so that we can cooperate with the leading players,' she added. Speaking to the Observer, Dr Mohammad Mahmoudi, Chief Executive Officer of Carbon Technologies, said that this collaboration is a testament to Oman's growing capacity in innovation-driven industries and its strategic openness to global partnerships. 'Together with R-Biopharm, we aim to elevate diagnostic standards, nurture Omani talent and contribute to national healthcare resilience,' Dr Mohammad added. Aligned with the objectives of Oman Vision 2040, the MoU supports national goals in biotechnology, scientific research and industrial innovation. Speaking on the sidelines of the signing ceremony, Eng Said bin Nasser al Salmi, Board Member of Carbon Technologies, said that the MoU would open up more opportunities to leverage Carbon Technologies as a leading Omani company and expand local R&D capabilities to serve both domestic and international markets in the healthcare industry and position Oman among the leading innovation hubs in such sectors. Dr Dirk Dressler, Head of Business Development at R-Biopharm AG, said, 'We are honoured to partner with Oman's Carbon Technologies. This collaboration reflects our confidence in Oman's capabilities and our shared commitment to delivering high-quality, accessible diagnostics across the region." 2025 © All right reserved for Oman Establishment for Press, Publication and Advertising (OEPPA) Provided by SyndiGate Media Inc. (
Al Etihad
3 days ago
- Al Etihad
Renowned orthopaedic experts bring advanced care to Abu Dhabi in August
11 Aug 2025 22:33 SAMIHAH ZAMAN (ABU DHABI)Patients looking for world-class orthopaedic care close to home can benefit from a duo of doctors headed to Abu Dhabi as part of the Department of Health – Abu Dhabi's (DoH) Visiting Physicians Munjed Al Muderis, a US-based consultant in orthopaedic surgery and Singapore-based Dr. Aymeric Lim, senior consultant of hand and reconstructive microsurgery, are seeing patients at two healthcare facilities in the capital, the DoH has announced. 'The DoH welcomes top-tier doctors from around the world to the Emirate during August, offering exceptions healthcare services through the Visiting Physicians Programme,' the authority announced. Dr. Munjed Al Muderis (L) and Dr. Aymeric Lim (R) Al Muderis practises at the St Mary Hosptial, Paley Institute at West Palm Beach, one of the largest centres in orthopaedics and limb lengthening in the United States. He specialises in limb lengthening, the treatment of diabetic feet, osseointegration for amputees, limb reconstruction, joint replacement, bone tumour treatment and paediatric orthopaedics. According to the DoH, he will see patients at the Burjeel Medical City between August 11 and part of the National University Hospital in Singapore, has 30 years of experience in micro hand surgeries, nerve surgery, tendon transfer, and the treatment of patients with severe crush or nerve injuries in the forearm. He will offer treatment services at the Sheikh Shakhbout Medical City between August 11 and DoH has urged patients and their families to directly contact the respective hospitals in order to book appointments. The authority's Visiting Physicians Programme – launched in 2021 with the aim of providing world-class care in Abu Dhabi – had enabled the treatment of over 3,200 patients in the emirate as of December 2024. Source: Aletihad - Abu Dhabi
